HIGH DESERT HEALTH SYSTEM
AMBULATORY SURGICAL CENTER

SUBJECT: XI-100 ADVERSE DRUG REACTIONS REPORTING	**POLICY #**: 1266
	VERSION: 1
APPROVED BY: Aram. Messerlian (CHIEF PHYSICIAN I ANESTHESIOLOGY), Beryl Brooks (ADMR,COMP AMB HEALTH CARE CENTER), Leila Adriano (NURSE MANAGER)	
DATE APPROVED: 09/15/2017	

PURPOSE: To identify and appropriately treat adverse drug reactions.

POLICY: Suspected adverse drug reactions occurring at the Ambulatory Surgery Center (ASC) shall be immediately reported to the Anesthesia staff and to the attending physician, if indicated, for appropriate action.

DEFINITION:

Adverse drug reaction (ADR): Any untoward reaction to a medication, which results in one or more of the following:

a. A dosage change
b. Discontinuation of the medication
c. Changing to a different medication
d. Treatment of symptoms which may include additional visits, hospitalization, or change in level of care.

Suspected adverse drug reactions are categorized as mild, moderate, or severe. The severity rating can include one or more criteria in any category.

Mild: Intervention was required, including the discontinuation of the drug, but no increase in stay was required.

Moderate: Caused hospitalization.

Severe: Reaction is life threatening, permanently disabling, requires admission to a critical care unit, requires hospitalization longer than 15 days, or contributes to the death of the patient.

PROCEDURE:

1. Notify anesthesiologist immediately upon identification of a suspected ADR in any ASC location. Additionally, notify the attending physician if the suspected ADR occurs in the preoperative holding area (POHA) or in the operating room (OR) during procedure performed under local anesthesia or moderate sedition.

2. The anesthesia staff and/or attending physician will order appropriate measures to reverse or modify the reaction.

HIGH DESERT HEALTH SYSTEM
AMBULATORY SURGICAL CENTER

SUBJECT: XI-100 ADVERSE DRUG REACTIONS	**POLICY #**: 1266
	VERSION: 1

3. The nurse, anesthesia and attending physician, if involved, will document in the patient's medical record the following information:

    - Date
    - Time
    - Medication name
    - Type of reaction
    - Treatment
    - Response to treatment

4. A –Safety Intelligence (SI) Report will be completed.

5. If deemed significant the Pharmacy shall report to the Food and Drug Administration (FDA) on Medwatch Report.

Original Date: 07/01/2003
Reviewed: 09/15/2017
Next Review Date: 09/15/2020
Previous Review Dates: 07/17/08; 07/05/2013
Previous Revise Dates: 01/06/09; 07/09/2013